Asset profile
AZD5492
Unknown / undisclosed
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Systemic Lupus Erythematosus · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
104 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 102 same-indication; 71 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD5492: this drug | Phase 1/2 | — | CD20 x CD3 | ||
| CND261 | Phase 1 | Biologic (subtype unspecified) | CD20 x CD3 | ||
| Plamotamab | Phase 1 | Monoclonal antibody | CD20 x CD3 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist |
…and 89 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.